Iterum Therapeutics plc

NasdaqCM:ITRM Stock Report

Mkt Cap: US$18.0m

Iterum Therapeutics Future Growth

How is Iterum Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-3.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqCM:ITRM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20255-78N/AN/A1
12/31/2024N/A-64N/AN/A1
12/31/2023N/A-74N/AN/A1
9/30/2022N/A-44-17-17N/A
6/30/2022N/A-11-16-16N/A
3/31/2022N/A4-18-18N/A
12/31/2021N/A-92-16-16N/A
9/30/2021N/A-99-22-22N/A
6/30/2021N/A-115-23-23N/A
3/31/2021N/A-135-28-28N/A
12/31/2020N/A-52-55-55N/A
9/30/2020N/A-64-69-69N/A
6/30/2020N/A-84-90-90N/A
3/31/2020N/A-99-94-94N/A
12/31/20190-103-82-82N/A
9/30/20190-104-83-83N/A
6/30/20191-97-85-85N/A
3/31/20191-85-79-79N/A
12/31/20181-77-77-77N/A
9/30/20181-62-62-62N/A
6/30/20181-45-40-40N/A
3/31/20181-36-37-37N/A
12/31/20171-29-31-31N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITRM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ITRM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ITRM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ITRM's revenue (75.6% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: ITRM's revenue (75.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ITRM's Return on Equity is forecast to be high in 3 years time


Discover growth companies